Glaukos Co. (NYSE:GKOS) Stake Raised by Algert Global LLC

Algert Global LLC grew its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 162.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,260 shares of the medical instruments supplier's stock after purchasing an additional 8,206 shares during the period. Algert Global LLC's holdings in Glaukos were worth $1,728,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of GKOS. O Shaughnessy Asset Management LLC acquired a new position in Glaukos in the first quarter valued at $294,000. Cetera Advisors LLC purchased a new position in shares of Glaukos during the 1st quarter worth about $213,000. Opaleye Management Inc. acquired a new stake in shares of Glaukos in the first quarter worth approximately $809,000. GAMMA Investing LLC increased its holdings in Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after purchasing an additional 486 shares during the last quarter. Finally, LVW Advisors LLC acquired a new position in shares of Glaukos in the 2nd quarter valued at approximately $213,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. This trade represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Glaukos Price Performance

GKOS stock traded up $1.96 during trading on Thursday, hitting $142.69. The company had a trading volume of 348,991 shares, compared to its average volume of 571,878. The business has a 50 day moving average of $133.56 and a 200 day moving average of $124.39. The firm has a market capitalization of $7.87 billion, a price-to-earnings ratio of -47.25 and a beta of 1.02. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a fifty-two week low of $59.58 and a fifty-two week high of $146.86.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same period in the previous year, the firm earned ($0.50) EPS. Glaukos's revenue was up 23.9% on a year-over-year basis. As a group, research analysts predict that Glaukos Co. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of research analyst reports. Piper Sandler set a $140.00 price target on shares of Glaukos in a research note on Thursday, October 17th. Stifel Nicolaus raised their price target on Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. upped their price objective on Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. Finally, Truist Financial upped their price target on shares of Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $135.45.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.